{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-22-000903","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2022-07-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.501171+00:00","generated_at":"2026-06-24T08:59:52.554608+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"USANA Q2 net sales $264M (-21% YoY), EPS $1.00 (-47%); FY2022 outlook reiterated","bullets":["Net sales $264M (-21% YoY, -18% constant currency); diluted EPS $1.00 vs $1.87 prior year.","Active customers 559K (-14% YoY); Greater China active customers 278K (-8% YoY, +9% sequentially).","FY2022 guidance maintained: net sales $1.015B-$1.065B, diluted EPS $3.85-$4.45.","No share repurchases during quarter; cash $230M; $83M remaining under buyback authorization.","COVID disruptions in mainland China and other key markets drove underperformance; inflationary pressures noted."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-22-000903","json":"https://secwatch.observer/filing/0001157523-22-000903.json","markdown":"https://secwatch.observer/filing/0001157523-22-000903.md","text":"https://secwatch.observer/filing/0001157523-22-000903.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752322000903/0001157523-22-000903-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752322000903/a52792490.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T08:59:52.554608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}